Testing A Combination Of 2 Clinical Drugs, An IAP Inhibitor And P38 Inhibitor, To Treat AML
Funder
National Health and Medical Research Council
Funding Amount
$200,890.00
Summary
Current treatments only cure 50% of Acute Myeloid Leukaemia (AML) patients, and novel approaches to treatment are desperately needed to improve survival of patients with leukaemia. One new drug, Birinapant, is currently being tested in clinical trials to treat AML. I have found that some AMLs are resistant to Birinapant treatment but the addition of a second drug (called “p38 inhibitors”) can now overcome this resistance. I will test how effective combining these two drugs can be to treat AML.
The focus of this research is the integration of innovative evidence-based, personalised physical activity behaviour change programs that can be delivered via print, web/email, telephone and mobile text-messaging into clinical settings. This research will evaluate the effectiveness of initiating these interventions at the point of interaction between patients and health professionals in current clinical environments for the purpose of improving physical activity levels amongst inactive patients.
Addressing Menstrual Health To Improve Adolescent Health And Development: Co-design Of An Acceptable And Scalable School-based Strategy In Myanmar
Funder
National Health and Medical Research Council
Funding Amount
$986,024.00
Summary
Our work in Myanmar has identified menstrual health to be a critical issue impacting on education and wellbeing for girls. We aim to produce an evidence-based and scalable strategy to improve adolescent menstrual health in Myanmar by: exploring needs and opportunities to address menstrual health across diverse school settings; Co-designing with girls and key stakeholders a strategy to improve menstrual health in Myanmar; piloting and evaluating the intervention package across diverse schools.
A Randomised Clinical Trial Of Internet-based Treatment For Binge Drinking And Depression In Young Australians
Funder
National Health and Medical Research Council
Funding Amount
$941,787.00
Summary
This project focuses on a common clinical problem that causes substantial functional, economic and health impacts; comorbid depression and binge drinking. These conditions are under-treated and peak in young adulthood. This project offers a low cost, wide reach, youth-appropriate treatment, which will have profound implications for service design and health policy. It relates to current Commonwealth initiatives in e-health and e-Psychology.
Snake envenoming is a neglected tropical disease and results in numerous deaths, psychological problems and economic burden. Antivenoms aren't readily available in resource poor countries. The CRE will investigate the effects of venom and antivenom to improve understanding of human envenoming. It will also develop tests for early diagnosis of envenoming and undertake clinical trials of antivenom. These studies will be translated back into clinical practice to improve treatment of snake bites.
The Value Of Providing Health Interventions For Heroin Use: A Cost Benefit Analysis
Funder
National Health and Medical Research Council
Funding Amount
$599,585.00
Summary
Heroin use and associated harms can be reduced through effective treatment. Past research has shown that treatment for heroin dependence can be relatively cost-effective, but not whether heroin treatment overall is a good investment. This unique study will estimate the net social benefit of heroin treatment, taking into account health, crime and family consequences. The results will help Australia respond better to this devastating health problem.
Investigation Of Dysfunction Of SIGMAR1 In Transgenic Mouse Models, A Novel Gene Implicated In Neurodegeneration
Funder
National Health and Medical Research Council
Funding Amount
$492,119.00
Summary
At present, there are no effective therapies for frontotemporal dementia or motor neuron disease. We have identified the SIGMAR1 gene as having a crucial role for these diseases. More importantly, there are therapeutically relevant small molecule drugs that are known to modulate the activity of this gene. We aim to determine the efficacy of pharmacological modulation of Sigma-1 receptor activity in mouse models of dementia.
First-Line Management Of Youth Depression: A Randomised Placebo-Controlled Trial Of Fluoxetine And Cognitive Behavioural Therapy
Funder
National Health and Medical Research Council
Funding Amount
$1,316,648.00
Summary
The study aims to establish how to best treat adolescents and young adults when they present to mental health clinics with moderate-to-severe depression. There is, at present, considerable uncertainty as to whether young people should be started on antidepressant treatment at the same time as psychotherapy, or whether psychotherapy alone be commenced first. The study aims to clarify this important issue by implementing a trial that compares both treatment approaches.
Optimising Medicine Regimens For People With Dementia: Maintaining Function, Maximising Quality Of Life And Preventing Adverse Events
Funder
National Health and Medical Research Council
Funding Amount
$715,017.00
Summary
I am a pharmacist based at Monash University. My expanding research team generates and applies evidence to optimise medicine regimens for people with dementia. My research assesses the risks and benefits of medicines for dementia and other health conditions. I will also focus on research training and capacity building. My research ensures people with dementia and their clinicians are equipped with the best evidence to inform medicines management decisions to optimise health outcomes.